Scott M Rocklage was interested in life science as a subject that he went on to study chemistry. He obtained his B.S in chemistry from the University of California, Berkeley. He went on to get a Ph.D. in chemistry from MIT and conducted his research from one of the Nobel Prize winners laboratory, Richard R Schrock.
After he was done with his studies, in the year 1990 to 1994, he became the CEO of the Nycomed Salutary Inc. In the year 1994- 2003 he became the founding CEO of the Cubist Pharmaceuticals Inc. His primary focus was on medicine, and he generated his ideas to life by interacting with physicians and scientist. He encouraged them to shape their views into pharmaceutical products that will cover the unmet illnesses. In 2003 he decided to join the 5 AM ventures as a mere partner and the following year he became the managing partner. This opened up more opportunities for him to serve as CEO at EPIRUS Biopharmaceuticals Inc. on May 11, 2016.
Other companies where he has served as CEO include; the Relypsa Inc from August 2007 to July 2014, Achaogen Inc from August 2004 to March 2015 and also llypsa Inc. Working at all those companies gave him extensive healthcare management experience and strategic leadership record which made him suitable for his position. For him to reach the far he has gone and be more productive, he was always well organized, time conscious and prioritized essential needs. He is a risk taker and never settled to work for other people hence his entrepreneur mindset.
His experience in healthcare management led to the approval of his drugs by the Foods and Drug Administration that was applied in the US. They included the Omniscan, Telascan, and Cubicin. He is an inventor of various patents in the US, and many people have taken an interest in his work. This has enabled him to get many reviews for his publication (https://ideamensch.com/scott-rocklage/). At the age of 61 years, Dr. Scott Rocklage is still connected to three board members in three organizations across ten different industries and other affiliations.